TDH Holdings Receives Nasdaq Deficiency Notice for Board and Audit Committee Non-Compliance

summarizeSummary

TDH Holdings, Inc. announced it received a Nasdaq notice for non-compliance with independent director and audit committee requirements following a recent director resignation, triggering a cure period.

check_boxKey Events

• Nasdaq Deficiency Notice Received

  TDH Holdings received a formal notice from Nasdaq on March 13, 2026, indicating non-compliance with Listing Rule 5605 regarding independent director and audit committee composition.

• Triggered by Director Resignation

  The non-compliance resulted from the resignation of independent director Qiu Li on March 11, 2026, which left the board without a majority of independent directors and the Audit Committee with fewer than three independent members.

• Cure Period Provided

  Nasdaq has granted the company a cure period until the earlier of its next annual meeting or March 11, 2027, to regain compliance by appointing a new independent director.

• No Immediate Listing Impact

  The notice has no immediate effect on the listing of the company's common shares, which will continue to trade on Nasdaq.

auto_awesomeAnalysis

This filing details the formal notification from Nasdaq regarding TDH Holdings' non-compliance with listing rules for board independence and audit committee composition. This deficiency stems directly from the resignation of an independent director on March 11, 2026, which was previously disclosed. While the company has a cure period until March 11, 2027, or earlier, to appoint a new independent director, this notice highlights a significant corporate governance issue that could ultimately impact the company's listing status if not resolved. Investors should monitor the company's progress in appointing a new independent director to regain compliance.